[Expression of Fas receptor and soluble @entity12 (sFasL) concentration in XXXX ].

@entity1 @entity981 @entity3052 @entity12 @entity1778
Apoptosis mediated by the interaction of cytotoxic T lymphocyte with blast cell via Fas receptor/ @entity12 ( @entity12 ) pathway is a one of the mechanisms of immunological @entity1778 surveillance. There is few data on possible blocking of Fas receptor by soluble form of Fas (sFasL) present in serum and the role of blast cells as the source of this ligand. Forty-eight @entity1 with de novo diagnosis of @entity3052 , 32 with myeloblastic (AML) and 16 with @entity981 ( @entity981 ) were studied. Fas expression on bone marrow @entity1778 was determined by flow cytomertic immunofluorescent analysis and serum concentration of sFasL assessed at presentation, in remission and in relapse. Blasts of all @entity1 expressed Fas at variable degree (0.8 to 100%). Fas expression was significantly higher on myelo--than on lymphoblasts. There was no relation between degree of Fas expression at diagnosis and remission rate. Concentration of sFasL in @entity3052 @entity1 at diagnosis was significantly higher than in healthy control group, decreased to normal values in remission and rose again in relapse. There was a negative correlation between Fas expression on blasts and sFasL concentration at the time of diagnosis. Results obtained suggest that blast cells could be the source of soluble @entity12 in @entity3052 @entity1 and that sFasL serum concentration could be used for monitoring of disease activity.
